International Journal of Hematology

, Volume 109, Issue 5, pp 622–626 | Cite as

Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma

  • Jose D. Sandoval-SusEmail author
  • Amanda Brahim
  • Alina Khan
  • Barbara Raphael
  • Ali Ansari-Lari
  • Marco Ruiz
Case Report


Primary effusion lymphoma (PEL) is a rare and aggressive herpesvirus-8 (HHV-8) driven B cell non-Hodgkin’s lymphoma (NHL) that is usually associated with human immunodeficiency virus (HIV) infection, and has a poor prognosis. PEL is comprised of two clinically distinct but pathologically similar variants: classic and extracavitary PEL. Based on retrospective series, treatment options include combined antiretroviral therapy (cART) in conjunction with chemotherapy regimens used in other forms of NHLs. Treatment outcomes with this approach are usually dismal and there is no standard of care. We present a case of a patient with HIV associated CD30+ extracavitary PEL unfit for multi-agent chemotherapy, who achieved a durable complete response with single agent brentuximab-vedotin and cART.


Primary effusion lymphoma Human immunodeficiency virus AIDS 



  1. 1.
    Nador RG, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88:645–56.Google Scholar
  2. 2.
    Sherdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRefGoogle Scholar
  3. 3.
    Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28:2313–8.CrossRefGoogle Scholar
  4. 4.
    Stebbing J, Gazzard B, Mandalia S, Teaque A, Waterston A, Marvin V, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22:2177–83.CrossRefGoogle Scholar
  5. 5.
    Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003;2:3948–54.CrossRefGoogle Scholar
  6. 6.
    Guillet S, Gerard L, Meignin V, Agbalika F, Cuccini W, Denis B, et al. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. Am J Hematol. 2016;91:233–7.CrossRefGoogle Scholar
  7. 7.
    Kim Y, Park CJ, Roh J, Huh J. Current concepts in primary effusion lymphoma and other effusion-based lymphomas. Korean J Pathol. 2014;48:81–90.CrossRefGoogle Scholar
  8. 8.
    Chen Y, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist. 2007;12:569–76.CrossRefGoogle Scholar
  9. 9.
    Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004;28(11):1401–16.CrossRefGoogle Scholar
  10. 10.
    Carbone A, Gloghini A, Vaccher E, Cerri M, Gaidano G, Dalla-Favera R, et al. Kapsoi’s sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas a tissue-based variant of primary effusion lymphoma. J Mol Diagn. 2005;7(1):17–27.CrossRefGoogle Scholar
  11. 11.
    Gaidano G, Gloghini A, Gattei V, Rossi MF, Cilia AM, Godeas C, et al. Association of Kaposi’s sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/Syndecan-1 antigen. Blood. 1997;90(12):4894–900.Google Scholar
  12. 12.
    Carbone A, Gloghini A, Larocca LM, Capello D, Pierconti F, Canzonieri V, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97(3):744–51.CrossRefGoogle Scholar
  13. 13.
    Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, Abino JF, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients With AIDS. J Clin Oncol. 2005;23(19):4372–80.CrossRefGoogle Scholar
  14. 14.
    Hoffmann C, Wolf E, Wyen C, Fatkenheuer G, Van Luzen J, Stellbrink HJ, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma. 2006;47(9):1872–80.CrossRefGoogle Scholar
  15. 15.
    Ribera JM, Garcia O, Grande C, Esteve J, Oriol A, Bergua J, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013;119(9):1660–8.CrossRefGoogle Scholar
  16. 16.
    Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378(22):1029–41.CrossRefGoogle Scholar
  17. 17.
    Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013;122(7):1233–42.CrossRefGoogle Scholar
  18. 18.
    Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798–804.CrossRefGoogle Scholar
  19. 19.
    Oregel KZ, Everett E, Zhang X, Nagaraj G. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. Expert Rev Anticancer Ther. 2016;16(3):279–83.CrossRefGoogle Scholar
  20. 20.
    Alderuccio JP, Desai A, Yepes MM, Chapman JR, Vega F, Lossos IS. Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma. Clin Case Rep. 2018;6(4):634–7.CrossRefGoogle Scholar
  21. 21.
    Oksenhendler E, Clauvel JP, Jouveshomme S, Davi F, Mansour G. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol. 1998;57(3):266.CrossRefGoogle Scholar
  22. 22.
    Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS. 2001;15(2):280–2.CrossRefGoogle Scholar
  23. 23.
    Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis. 2014;59(1):106–14.CrossRefGoogle Scholar
  24. 24.
    Rubinstein PG, Moore PC, Rudek MA, Henry DH, Ramos JC, et al. Brentuximab bedouin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. AIDS. 2018;32(5):605–11.Google Scholar
  25. 25.
    Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al. Rituximan plus concurrent infusions EPOCH chemotherapy is highly effective in HIV-associated B-Cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008–16. Scholar
  26. 26.
    Sabattini FB, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.Google Scholar
  27. 27.
    Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65.CrossRefGoogle Scholar
  28. 28.
    Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.CrossRefGoogle Scholar
  29. 29.
    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9.CrossRefGoogle Scholar
  30. 30.
    Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood. 2018;131(19):2120–4.CrossRefGoogle Scholar
  31. 31.
    Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–44.CrossRefGoogle Scholar
  32. 32.
    Boulanger E, Daniel MT, Agbalika F, Oksenhendler E. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol. 2003;73(3):143–8.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare SystemH. Lee Moffitt Cancer CenterPembroke PinesUSA
  2. 2.Department of PharmacyMemorial Healthcare SystemPembroke PinesUSA
  3. 3.Department of Diagnostic RadiologyMemorial Healthcare SystemPembroke PinesUSA
  4. 4.Division of Hematopathology, Department of Anatomic and Clinical PathologyMemorial Healthcare SystemHollywoodUSA

Personalised recommendations